Search results
Results From The WOW.Com Content Network
Canagliflozin, sold under the brand name Invokana among others, is a medication used to treat type 2 diabetes. [3] It is used together with exercise and diet. [3] It is not recommended in type 1 diabetes. [3] It is taken by mouth. [3] Common side effects include vaginal yeast infections, nausea, constipation, and urinary tract infections. [3]
Canagliflozin was the first SGLT2 inhibitor to be approved for use in the United States. It was approved in March 2013, under the brand name Invokana and it was also marketed throughout the EU under the same name. [26] [27] Dapagliflozin, approved under the name Forxiga, was approved by the EU in 2012, the first SGLT2 inhibitor approved ...
Canagliflozin, dapagliflozin, and empagliflozin should each be stopped at least three days before, and ertugliflozin should be stopped at least four days before scheduled surgery. [5] Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing.
[3] [20] C-glucoside bearing thiazole at the distal ring on canagliflozin has shown good physicochemical properties that can lead to a clinical development, but still has the same anti-diabetic activity as dapagliflozin, as shown in tables 1 and 2. Song and his partners did preparate thiazole compound by starting with carboxyl acid.
Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. [6] [7] [9] It is also used to treat adults with heart failure and chronic kidney disease.
Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and works by increasing sugar loss in urine. [ 2] Empagliflozin was approved for medical use in the United States and in the European Union in 2014. [ 11][ 22][ 23] It is on the World Health Organization's List of Essential Medicines. [ 24]
Atypical antipsychotics include: Amisulpride (Solian) – approved in low doses as a monotherapy for persistent depression. Lumateperone (Caplyta) – approved as a monotherapy for bipolar depression. Lurasidone (Latuda) – approved as a monotherapy for bipolar depression. Quetiapine (Seroquel) – approved as a monotherapy for bipolar depression.
Remogliflozin etabonate (INN/USAN) [2] is a drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes.Remogliflozin was discovered by the Japanese company Kissei Pharmaceutical and is currently being developed by BHV Pharma, a wholly owned subsidiary of North Carolina, US-based Avolynt, and Glenmark Pharmaceuticals through a collaboration with ...